Peptide Administration Routes: SC, IP, IV, and Intranasal Compared

One of the most consequential decisions in peptide research design is the choice of administration route. The same compound at the same dose can produce dramatically different pharmacokinetic profiles, tissue exposures, and experimental outcomes depending on whether it is delivered subcutaneously, intraperitoneally, intravenously, or intranasally. Yet the literature often presents dosing protocols without explaining the rationale behind route selection — or acknowledging how results from one route translate (or don't) to another.

This guide covers the four most common routes used in preclinical peptide research: subcutaneous (SC), intraperitoneal (IP), intravenous (IV), and intranasal (IN). For each route, we review the relevant pharmacokinetics, bioavailability considerations, practical constraints, and the specific peptide research contexts where each approach is most appropriate.

Why Route of Administration Matters

Peptides face a unique set of pharmacokinetic challenges. Unlike small-molecule drugs, they are substrates for ubiquitous proteases in blood, tissue, and the gastrointestinal tract. Many peptides are also too large or too hydrophilic to cross epithelial barriers without active transport. These properties mean that the path from injection site to target tissue is not merely a logistical detail — it fundamentally shapes which concentrations reach which compartments, and for how long.

Two key parameters govern this discussion: bioavailability (the fraction of the administered dose that reaches systemic circulation in active form) and Tmax (the time to peak plasma concentration). Route selection determines both. A compound with a 30-minute plasma half-life delivered SC may produce a near-identical AUC to the same compound delivered IV, but the Cmax will be lower and Tmax substantially delayed — which matters enormously if the biological effect requires rapid peak exposure rather than sustained low-level presence.

Subcutaneous (SC) Administration

Subcutaneous injection deposits the compound into the loose connective tissue between the dermis and the underlying fascia. Absorption into systemic circulation occurs primarily via capillary uptake, with larger peptides (>5 kDa) absorbed more slowly via lymphatic drainage. This creates a depot effect: SC injection typically produces lower peak concentrations (Cmax) but extended absorption windows compared to IV or IP.

In rodent models, SC bioavailability for peptides varies widely — from 20–40% for large hydrophilic peptides like tesamorelin to near-complete (>80%) for smaller optimized sequences like ipamorelin. The site of injection also matters: scruff-of-neck SC injections in mice show faster absorption than flank injections due to differences in local vascularity and adipose thickness. Researchers should standardize injection sites across all animals in a study.

Pharmacokinetic Profile

SC injection typically produces a Tmax of 15–60 minutes in rodents for most research peptides, with a gradual decline over 2–6 hours depending on half-life. Because absorption from the SC depot is rate-limiting, the apparent half-life observed following SC injection is often longer than the true plasma elimination half-life. This 'flip-flop' pharmacokinetics effect is especially pronounced for peptides with very short half-lives, such as GHRP-2 (t½ ~20-30 min IV vs apparent 60-90 min SC).

For GH axis peptides — where pulsatile GH release is the desired endpoint — SC delivery is generally preferred over IV precisely because it produces a more physiological rise-and-fall curve. Studies comparing SC and IV ipamorelin at equivalent doses in rats have shown comparable GH AUC but a flatter, broader SC curve versus a sharp spike-and-decline IV profile. Downstream IGF-1 elevation at 24 hours was similar between routes in these comparisons.

When to Use SC

SC is the workhorse route for most chronic peptide studies in rodents. It is technically simple, minimally stressful for the animal (compared to repeated IV cannulation), and produces consistent depot kinetics when injection sites are standardized. It is the most appropriate route for studies assessing chronic effects on body composition, IGF-1, or tissue remodeling outcomes, where peak plasma concentration is less important than cumulative exposure.

Intraperitoneal (IP) Administration

IP injection delivers compound into the peritoneal cavity, where absorption occurs primarily via the portal venous circulation. This route is extraordinarily common in mouse research — arguably overused — because it is technically easy, accommodates large volumes (up to 2 mL/mouse, 5 mL/rat), and produces faster and more consistent absorption than SC for most peptides.

The pharmacokinetic signature of IP administration is intermediate between SC and IV: Tmax is typically 10–30 minutes in mice, with bioavailability ranging from 60–100% for most small-to-medium peptides. The portal venous drainage pathway means that compounds absorbed IP pass through the liver before reaching systemic circulation — a 'first-pass' effect that is important to consider for peptides with known hepatic metabolism, though most research peptides are cleared by circulating proteases rather than hepatic enzymes.

Practical Advantages and Limitations

IP injection is technically more forgiving than IV — the intra-abdominal space tolerates imprecise needle placement better than a tail vein. For acute bolus studies requiring rapid and near-complete absorption without the technical demands of IV catheterization, IP is frequently the practical choice. Most published BPC-157, DSIP, and KPV rodent studies use IP delivery at doses of 10–100 µg/kg.

The limitations are equally important. IP injection can cause peritoneal irritation with repeated administration or with formulations containing DMSO, benzyl alcohol at high concentrations, or low-pH acetic acid. Adhesions from prior IP injections may reduce absorption consistency in chronic studies. There is also an underappreciated variability problem: aspiration of bowel, bladder, or organ during IP injection delivers compound extravascularly with no absorption — a source of data noise that researchers often attribute to biological variability.

Intravenous (IV) Administration

IV administration delivers compound directly into systemic circulation, bypassing all absorption barriers. Bioavailability is by definition 100%, and Tmax is effectively zero (or the duration of the infusion). This makes IV delivery the pharmacokinetic gold standard: it provides the most precise dose control and enables calculation of true plasma clearance and volume of distribution.

In mice, tail vein injection is the standard IV route. It requires warming the animal to dilate the lateral tail veins, technical skill to cannulate the 0.5mm vessel without subcutaneous extravasation, and strict volume limits (typically ≤200 µL per injection). In rats, tail vein injection is more accessible but still technically demanding. Jugular or femoral vein catheterization enables repeated IV dosing and automated sampling but requires surgical placement under anesthesia and sterile surgical technique.

Pharmacokinetic Utility

IV administration is indispensable for pharmacokinetic characterization studies. To measure true t½, Vd, and AUC, researchers need IV data as the reference point. The Arvat 1997 IV bolus data establishing GHRP-2's GH peak of 50–70 ng/mL at 1–2 mcg/kg, the Ghigo 1994 hexarelin GH peaks of 70–90 ng/mL, and the Dhillo 2005 kisspeptin-10 LH data were all generated via IV bolus — routes that ensure full and immediate systemic exposure necessary for dose-response characterization.

IV delivery is also appropriate when the research question requires precise temporal control over plasma concentration — such as when correlating GH pulses with downstream gene expression changes on a minute-by-minute timescale. For studies where the endpoint can tolerate a slower, sustained exposure curve, SC or IP will be more practical.

Intranasal (IN) Administration

Intranasal delivery has attracted growing interest for CNS-active peptides because the olfactory and trigeminal pathways provide a potential direct route from the nasal mucosa to brain tissue, bypassing the blood-brain barrier (BBB). The olfactory nerve (CN I) terminates in the olfactory bulb after passing through the cribriform plate, and the trigeminal nerve (CN V) innervates both nasal and intracranial structures — creating anatomical corridors for neuropeptide transport that are not available via systemic routes.

For peptides like oxytocin, Selank, Semax, and PT-141, intranasal delivery is the primary research route precisely because it enables CNS exposure at doses that would require much higher systemic concentrations via SC/IP to achieve equivalent brain tissue levels. Semax's intranasal bioavailability studies have demonstrated 0.5–3% CNS uptake fraction following nasal delivery, which, while numerically small, produces pharmacologically relevant hypothalamic concentrations because the direct olfactory pathway bypasses dilution into the 3L systemic plasma volume.

Rodent Intranasal Protocol Considerations

Intranasal delivery in rodents is technically demanding due to nasal geometry. Standard protocols anesthetize the animal, position it supine, and deliver small volumes (2–5 µL per nostril) via micropipette. Volumes exceeding 5 µL per nostril in mice are swallowed rather than absorbed nasally — an important constraint that limits the total intranasal dose achievable. Rats tolerate slightly larger volumes (10–15 µL per nostril) and are often preferred for IN peptide studies requiring higher doses.

The Dolotov 2006 Semax data and the Semenova 2010 Selank studies both used IN delivery in rats at concentrations of 10–50 µg per animal, establishing that IN peptide administration produces detectable CNS biomarkers (BDNF elevation, GABA-A receptor sensitivity) within 30–60 minutes. Researchers replicating these studies should note that nasal mucosal absorption efficiency varies with formulation pH, viscosity, and vehicle — and that DMSO-containing formulations, while enhancing penetration, may confound results due to DMSO's own CNS activity.

Systemic Absorption via Intranasal Route

Not all intranasal absorption is via the olfactory pathway. A significant fraction of the nasally administered dose is swept to the nasopharynx and swallowed — particularly in conscious animals — and absorbed via the GI mucosa. This systemic fraction contributes to plasma levels and is the primary absorption route for intranasal oxytocin in humans (where only 1–2% of the intranasal dose is detectable in CSF, according to Neumann 2013 data). Researchers should design controls that account for this systemic component when attributing CNS effects to direct olfactory transport.

Route Comparison: Practical Decision Framework

Dose Extrapolation Across Routes

When translating published protocols from one route to another, researchers should not assume dose equivalence. The standard approach is to use relative bioavailability data to calculate dose adjustments: if a compound's SC bioavailability is 50% relative to IV, doubling the SC dose theoretically produces equivalent AUC — though Cmax and Tmax will still differ. In the absence of published comparative PK data for a specific compound, conservative practice is to use the same dose and document the route, then compare results to the closest available reference study.

For GH axis peptides specifically, route equivalence is complicated by the pulsatile nature of GH secretion. The GH peak triggered by IV bolus GHRP-2 is diagnostically useful (as in Arvat 1997) but not achievable at the same intensity via SC. SC delivery of an equivalent dose produces a blunted, delayed GH peak — but the integrated 24-hour IGF-1 response (the more relevant endpoint for chronic studies) is often comparable. Selecting the appropriate pharmacodynamic endpoint is as important as selecting the route.

Formulation Compatibility by Route

Route selection constrains formulation choices. IV-compatible formulations must be sterile, isotonic (270–310 mOsm), pH 6.5–7.5, and free of particulates. BAC water — the standard reconstitution vehicle for most research peptides — contains 0.9% benzyl alcohol, which causes hemolysis at concentrations above 1–2% in IV preparations and should not be used for IV delivery. For IV administration, reconstitute in sterile saline (0.9% NaCl) or sterile water, and verify osmolality if injecting volumes >100 µL.

SC and IP injection are considerably more tolerant of formulation variation. BAC water at standard concentrations (0.9% benzyl alcohol) is well-tolerated SC and IP in rodents at volumes up to 1 mL/100g body weight. Acetic acid vehicles (0.1–1% used for some lyophilized peptides that require acid conditions for solubility) are tolerated SC at low volumes but cause peritoneal irritation with repeated IP injection — use saline dilution to reduce final acetic acid concentration below 0.1% for IP delivery.

Key Research Design Considerations

First, match route to mechanistic hypothesis. If you're studying CNS effects of a peptide, SC or IP delivery requires demonstration that the compound crosses the BBB at the doses used — or the endpoint must be downstream of a peripheral mechanism (e.g., vagal afferent signaling for gut-brain axis effects). CNS-active hypotheses for systemically-delivered peptides require BBB permeability data or a validated surrogate measure.

Second, control for vehicle effects. Benzyl alcohol, acetic acid, and DMSO each have biological activities at concentrations present in typical reconstituted peptide solutions. Vehicle-injected controls must receive the same formulation vehicle at the same volume and route as the treatment group. Many published peptide studies have inadequate vehicle controls — avoid this limitation in your study design.

Third, standardize injection timing relative to circadian phase. GH axis peptides administered SC at lights-off in mice (when GH pulsatility is highest) will produce different IGF-1 responses than the same dose at lights-on. GLP-1 analogs administered IP during the active phase (lights-off in nocturnal rodents) interact with normal postprandial GLP-1 secretion differently than administration during the inactive phase. Record and standardize injection timing in all protocols.

Fourth, for IP delivery, verify injection site accuracy at the end of the study by necropsy examination. If more than 10–15% of animals show evidence of subcutaneous or organ injection rather than intraperitoneal placement, your PK assumption is violated and results should be interpreted cautiously.